Nektar (NKTR) Director Diana Brainard Receives 6,000 RSU Award

What Happened Diana Brainard, a director of Nektar Therapeutics (NKTR), received equity awards on September 23, 2026: 2,000 shares reported as acquired and 4,000 shares reported as a derivative acquisition. Both items were recorded at $0.00 (no cash paid), reflecting equity compensation (restricted stock units / contingent rights to common stock). The Form 4 was filed on September 25, 2026.

Key Details

• Transaction date: 2026-09-23; Filing date: 2026-09-25 (timely filing).
• Reported amounts: 2,000 shares (acquired) and 4,000 derivative shares (acquired) — total 6,000 RSU-type awards; reported price $0.00, reported cash value $0.
• Shares owned after transaction: not specified in the filing.
• Footnotes of note:
  • F1: Awards are restricted stock units (each RSU converts to one share upon vesting).
  • F2: “This RSU award vests in full one year following September 23, 2026” (i.e., likely vests ~Sept 23, 2027).
  • F3: All securities amounts are adjusted for a 1-for-15 reverse stock split effected June 8, 2025.
  • F4: Notes a stock option vesting schedule (monthly over one year beginning Sept 23, 2026) referenced in the filing.
• Transaction code: A (award/grant).

Context

• These entries reflect equity compensation grants (RSUs/derivatives), not open-market purchases or sales; they do not by themselves indicate buying or selling sentiment.
• RSUs are contingent: recipient typically receives actual shares only upon vesting and any applicable taxes/withholding.
• The filing shows no cash exercise or sale; the reported $0 price reflects a grant, not market value.